oxytocin + carboprost

Oxytocin + carboprost is a combination of two uterotonic agents used in obstetric practice, primarily for the prevention and treatment of postpartum hemorrhage (PPH), especially in high-risk patients undergoing cesarean delivery. Oxytocin is a peptide hormone that acts as an agonist at the oxytocin receptor on uterine smooth muscle, stimulating rhythmic contractions to facilitate labor and reduce bleeding after delivery. Carboprost is a synthetic analogue of prostaglandin F2α that binds to prostaglandin receptors on the uterus, inducing strong myometrial contractions and promoting hemostasis at the placental site. The combination may be used when monotherapy with either agent is insufficient or when enhanced efficacy in controlling uterine atony or hemorrhage is desired. Both drugs are administered parenterally (typically intramuscularly or intravenously). Common adverse effects include gastrointestinal symptoms such as nausea and vomiting; serious side effects are rare but can include bronchospasm (carboprost) or hypotension (oxytocin)[1][3][5][6][8].

Other names

oxytocin and carboprostoxytocin plus carboprost